Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)
- Conditions
- Pain
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT01780233
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States
Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions
- Conditions
- Bioavailability
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 88
- Registration Number
- NCT01448772
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions, Austin, Texas, United States
Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: LEP-ETU
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2012-08-24
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 70
- Registration Number
- NCT01190982
- Locations
- 🇮🇳
Indo-American Cancer Institute and Research Center, Banjara Hills, Hyderabad, India
🇮🇳P.D. Hinduja Antional Hospital & Medical Research Center, Mahim, Mumbia, India
🇮🇳Jaslok Hospital and Research Center, Mumbai, India
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: Liposome Entrapped Docetaxel (LE-DT)
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT01188408
- Locations
- 🇺🇸
Georgetown University Medical center, Washington, District of Columbia, United States
🇺🇸Providence Portland Medical center, Portland, Oregon, United States
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Liposome Entrapped Docetaxel (LE-DT)
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2012-09-12
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT01186731
- Locations
- 🇺🇸
Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, United States
Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Drug: LE-DT
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01151384
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸TGEN/Scottsdale Clinical Research Institute, Scottsdale, Arizona, United States
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
- Conditions
- MucositisPainUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 18
- Registration Number
- NCT00956254
- Locations
- 🇺🇸
InSys Therapeutics, Incorporated, Scottsdale, Arizona, United States
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 319
- Registration Number
- NCT00538863
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 130
- Registration Number
- NCT00538850
- Locations
- 🇺🇸
InSys Therapeutics, Incorporated, Chandler, Arizona, United States
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
- Conditions
- Recurrent Malignant Glioma
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT00378235
- Locations
- 🇺🇸
Dana-Farber Cancer Institute-Dept of Pediatric Oncology, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Duke University Medical Center-Dept. of Pediatrics, Medicine & Surgery, Durham, North Carolina, United States